Trials / Completed
CompletedNCT00163202
Comparative Atorvastatin Pleiotropic Effects
A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 330 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented coronary artery disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood samples | |
| DRUG | Atorvastatin |
Timeline
- Start date
- 2002-06-01
- Completion
- 2005-08-01
- First posted
- 2005-09-13
- Last updated
- 2021-02-18
Locations
74 sites across 7 countries: Canada, Czechia, France, Poland, Romania, Russia, Slovakia
Source: ClinicalTrials.gov record NCT00163202. Inclusion in this directory is not an endorsement.